Scarica l'app Stockscreener
5.45
3.02%
-0.17
Dopo l'orario di chiusura:
5.44
-0.010
-0.18%
Alvotech Borsa (ALVO) Ultime notizie
Alvotech Cash Flow – HAN:Z45 - TradingView
Average basic shares outstanding of Alvotech – HAN:Z45 - TradingView
Alvotech stock draws Barclays upgrade ahead of FDA decisions - AD HOC NEWS
ALVO Stock Price, Quote & Chart - ChartMill
Alvotech (NASDAQ:ALVO) Shares Up 3.5%Here's What Happened - MarketBeat
Alvotech (ALVO) Jumped, But What Is Driving Attention Now? - simplywall.st
Alvotech (NASDAQ:ALVO) Trading Up 7.2%Should You Buy? - MarketBeat
Can Alvotech (NASDAQ:ALVO) Change Its Healthcare Story? - Kalkine Media
Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Positive Report for Alvotech (ALVO) from Barclays - theglobeandmail.com
Why This Biotech Stock Just Got a Rare Double Upgrade - Barron's
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside - TradingView
Alvotech Jumps Most Since December After Barclays Doubles Price Target to $8 - finance.biggo.com
Alvotech Shares Rise After Double Upgrade From Barclays - marketscreener.com
Alvotech stock surges on Barclays upgrade to Overweight - Investing.com
Alvotech stock surges on Barclays upgrade to Overweight By Investing.com - Investing.com South Africa
Alvotech (NASDAQ:ALVO) Shares Gap UpHere's What Happened - MarketBeat
Alvotech stock gains on double upgrade at Barclays (ALVO:NASDAQ) - Seeking Alpha
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday - benzinga.com
Alvotech Price Target Raised to $8.00/Share From $4.00 by Barclays - Moomoo
Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price Target - Yahoo Finance
Why is Alvotech stock rallying 5% today? - Investing.com
Barclays Upgrades Alvotech(ALVO.US) to Buy Rating, Raises Target Price to $8 - Moomoo
Barclays Upgrades Alvotech (NASDAQ: ALVO) Stock As FDA Inspection Clears Path To U.S. Approvals - foreignpolicyjournal.com
Barclays upgrades Alvotech stock rating on FDA approval outlook - Investing.com
Certain Stock Options of Alvotech are subject to a Lock-Up Agreement Ending on 14-SEP-2026. - marketscreener.com
How FDA Filing Acceptance Will Impact Alvotech (ALVO) Investors - simplywall.st
What Is Putting Alvotech Stock in Focus? (NASDAQ:ALVO) - Kalkine Media
Citadel Advisors LLC Makes New $6.38 Million Investment in Alvotech $ALVO - MarketBeat
Understanding the Setup: (ALVO) and Scalable Risk - Stock Traders Daily
Alvotech (ALVO) Is Up 7.5% After FDA Accepts Review Of Key Entyvio Biosimilar AVT80 - simplywall.st
Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars - marketscreener.com
Takeda Files Second Vedolizumab Biosimilar BPCIA Action with Alvotech in the Firing Line - Pearce IP
Alvotech’s Subcutaneous Biosimilar Vedolizumab BLA Accepted for Review by FDA - Pearce IP
Alvotech (NASDAQ:ALVO) Shares Up 5.4%Here's What Happened - MarketBeat
FDA to review Alvotech (Nasdaq: ALVO) subcutaneous Entyvio biosimilar - stocktitan.net
Alvotech Says FDA Accepted Biologics License Application for AVT80 - marketscreener.com
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations - Yahoo Finance
Update: Alvotech Shares Rise After FDA Accepts Biologics License Application for AVT80 - Yahoo Finance
Alvotech (ALVO) Is Up 11.7% After Lotus Biosimilar Licensing Deal and 2026 Guidance Update – Has The Bull Case Changed? - simplywall.st
Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical - Yahoo Finance
Alvotech (ALVO) Stock Still Trades At A Discount After A 57% Rally - simplywall.st
Alvotech to present at upcoming investor conferences in September - Yahoo Finance
Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground - simplywall.st
Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says - Yahoo Finance
Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update - Sahm
ALVOTECH ($ALVO) Releases Q2 2026 Earnings - Moomoo
Alvotech licenses durvalumab and emicizumab biosimilar candidates to Lotus in ~$150M deal - Dealroom
Alvotech Targets Three U.S. Biosimilar Decisions In Q4 After FDA Manufacturing Inspection Closes - Pulse 2.0
Teleconferência de Resultados do 2T26 da Alvotech (ALVO): Guidance Reafirmado - TradingKey
Alvotech (NASDAQ:ALVO) Builds Momentum Around Biosimilar Expansion - Kalkine Media
Alvotech 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALVO) 2026-08-21 - Seeking Alpha
Alvotech, Lotus Ink Biosimilar Licensing and Commercialization Pact in US, Asia - Contract Pharma
Alvotech (NASDAQ:ALVO) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Alvotech licenses two early-stage biosimilar candidates to Lotus for USD 150m - AllSci
Alvotech (NASDAQ: ALVO) bets on U.S. biosimilars with Lotus - Stock Titan
Alvotech Enters Licensing, Commercialization Deal for Two Biosimilars in US, Certain Asian Markets - marketscreener.com
Alvotech Enters Strategic Licensing and Commercialization Agreement with Lotus Pharmaceutical for AVT34 and AVT87 - Quiver Quantitative
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for ... - Enidnews.com
Alvotech and Lotus sign deal for proposed versions of $6.1B and $5.8B medicines - Stock Titan
Alvotech Q2 2026 Earnings Call Transcript - Sahm
Alvotech (ALVO) Stock Rises On Guidance Resolve Despite Lingering Loss Risk - simplywall.st
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):